To examine the efficacy of telbivudine ( LdT ) + adefovir ( ADV ) vs continuation of lamivudine ( LAM ) + ADV in patients with LAM-resistant chronic hepatitis B ( CHB ) who show a suboptimal response to LAM + ADV.